SG11201401649VA - Albumin binding antibodies and binding fragments thereof - Google Patents

Albumin binding antibodies and binding fragments thereof

Info

Publication number: SG11201401649VA
Authority: SG; Singapore
Prior art keywords: binding; antibodies; albumin; fragments; binding fragments
Prior art date: 2011-11-11

Application number

SG11201401649VA

Inventor

Ralph Adams

Pallavi Bhatta

Sam Phillip Heywood

David Paul Humphreys

Original Assignee

Ucb Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-11-11

Filing date

2012-11-09

Publication date

2014-07-30

2012-11-09 Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa

2014-07-30 Publication of SG11201401649VA publication Critical patent/SG11201401649VA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Otolaryngology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)

SG11201401649VA 2011-11-11 2012-11-09 Albumin binding antibodies and binding fragments thereof SG11201401649VA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161558559P	2011-11-11	2011-11-11
PCT/EP2012/072335 WO2013068571A1 (en)	2011-11-11	2012-11-09	Albumin binding antibodies and binding fragments thereof

Publications (1)

Publication Number	Publication Date
SG11201401649VA true SG11201401649VA (en)	2014-07-30

Family

ID=47358092

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201401649VA SG11201401649VA (en)	2011-11-11	2012-11-09	Albumin binding antibodies and binding fragments thereof

Country Status (24)

Country	Link
US (2)	US9803004B2 (en)
EP (1)	EP2776466B1 (en)
JP (1)	JP6411214B2 (en)
KR (1)	KR102048382B1 (en)
CN (1)	CN103946237B (en)
AU (1)	AU2012335496B2 (en)
BR (1)	BR112014011304B1 (en)
CA (1)	CA2856216C (en)
CY (1)	CY1119647T1 (en)
DK (1)	DK2776466T3 (en)
EA (1)	EA033766B1 (en)
ES (1)	ES2649098T3 (en)
HR (1)	HRP20171608T1 (en)
HU (1)	HUE037142T2 (en)
IL (1)	IL232226B (en)
IN (1)	IN2014DN03451A (en)
LT (1)	LT2776466T (en)
MX (1)	MX351502B (en)
NO (1)	NO2839445T3 (en)
PL (1)	PL2776466T3 (en)
PT (1)	PT2776466T (en)
SG (1)	SG11201401649VA (en)
SI (1)	SI2776466T1 (en)
WO (1)	WO2013068571A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA112203C2 (en) *	2011-11-11	2016-08-10	Юсб Фарма С.А.	Fusion protein of a biospecific antibody that binds to human OX40 and serum human albumin
GB201208370D0 (en)	2012-05-14	2012-06-27	Ucb Pharma Sa	Antibodies
GB201223276D0 (en) *	2012-12-21	2013-02-06	Ucb Pharma Sa	Antibodies and methods of producing same
RU2661087C2 (en) *	2013-08-30	2018-07-11	Априлбио Ко., Лтд	Hybrid structure, including antigen-binding fragment specific to serum albumin and effector component and methods for preparation thereof
GB201320066D0 (en)	2013-11-13	2013-12-25	Ucb Pharma Sa	Biological products
GB201411320D0 (en) *	2014-06-25	2014-08-06	Ucb Biopharma Sprl	Antibody construct
GB201506869D0 (en)	2015-04-22	2015-06-03	Ucb Biopharma Sprl	Method
GB201506870D0 (en) *	2015-04-22	2015-06-03	Ucb Biopharma Sprl	Method
GB201506868D0 (en)	2015-04-22	2015-06-03	Ucb Biopharma Sprl	Method for protein purification
CN115109158A (en)	2015-05-07	2022-09-27	阿吉纳斯公司	anti-OX 40 antibodies and methods of use thereof
GB201508180D0 (en)	2015-05-13	2015-06-24	Ucb Biopharma Sprl	Antibodies
KR20180025962A (en)	2015-07-06	2018-03-09	유씨비 바이오파마 에스피알엘	Tau binding antibody
EP3319984A1 (en)	2015-07-06	2018-05-16	UCB Biopharma SPRL	Tau-binding antibodies
EP3359688B1 (en)	2015-10-05	2021-06-16	UCB Biopharma SRL	Molecular signatures for use in diagnosis and response to treatment analysis of autoimmune diseases
CA3007233A1 (en)	2015-12-02	2017-06-08	Agenus Inc.	Antibodies and methods of use thereof
GB201602938D0 (en)	2016-02-19	2016-04-06	Ucb Biopharma Sprl	Protein purification
BR112018071288A2 (en) *	2016-05-01	2019-02-26	Ucb Biopharma Sprl	modified affinity serum protein carrier binding domain
GB201610198D0 (en) *	2016-06-10	2016-07-27	Ucb Biopharma Sprl	Anti-ige antibodies
MA46770A (en)	2016-11-09	2019-09-18	Agenus Inc	ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
EP3583125A2 (en)	2017-02-16	2019-12-25	Sonnet Bio Therapeutics	Albumin binding domain fusion proteins
WO2018224439A1 (en) *	2017-06-05	2018-12-13	Numab Innovation Ag	Novel anti-hsa antibodies
KR20200015505A (en)	2017-06-05	2020-02-12	누맙 세러퓨틱스 아게	New Anti-HSA Antibody
GB201711481D0 (en)	2017-07-17	2017-08-30	Ucb Biopharma Sprl	Protein purification
KR102204315B1 (en) *	2018-11-16	2021-01-18	한국세라믹기술원	Affibody specific to human serum albumin and its use
EP4007771A1 (en)	2019-08-02	2022-06-08	UCB Biopharma SRL	Methods for purifying antibodies
CN112409480B (en) *	2019-08-20	2024-08-27	四川科伦博泰生物医药股份有限公司	Serum albumin binding proteins and uses thereof
GB201919061D0 (en)	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Multi-specific antibody
GB201919058D0 (en)	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Multi-specific antibodies
GB201919062D0 (en)	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Antibody
GB202001447D0 (en)	2020-02-03	2020-03-18	Ucb Biopharma Sprl	Antibodies
WO2021191424A1 (en)	2020-03-27	2021-09-30	UCB Biopharma SRL	Autonomous knob domain peptides
KR102367488B1 (en) *	2020-06-29	2022-02-25	주식회사 프로테인웍스	A analysis method of single chain antibody fragment(scFv)-albumin drug conjugate
US20230374148A1 (en)	2020-10-15	2023-11-23	UCB Biopharma SRL	Binding molecules that multimerise cd45
EP4255926A1 (en)	2020-12-07	2023-10-11	UCB Biopharma SRL	Multi-specific antibodies and antibody combinations
AU2021398385A1 (en)	2020-12-07	2023-07-13	UCB Biopharma SRL	Antibodies against interleukin-22
CN115181751A (en) *	2021-04-02	2022-10-14	苏州博腾生物制药有限公司	Chimeric antigen receptors targeting albumin and methods of use thereof
WO2022233764A1 (en)	2021-05-03	2022-11-10	UCB Biopharma SRL	Antibodies
CN117545504A (en) *	2021-06-07	2024-02-09	上海济煜医药科技有限公司	Antigen binding proteins against human serum albumin
GB202111905D0 (en)	2021-08-19	2021-10-06	UCB Biopharma SRL	Antibodies
WO2023242271A1 (en)	2022-06-15	2023-12-21	UCB Biopharma SRL	Fusion protein for the prevention, treatment or amelioration of kidney diseases
AR129610A1 (en)	2022-06-15	2024-09-11	UCB Biopharma SRL	FUSION PROTEINS
US12134635B1 (en)	2023-12-29	2024-11-05	Sonnet BioTherapeutics, Inc.	Interleukin 18 (IL-18) variants and fusion proteins comprising same

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5677425A (en)	1987-09-04	1997-10-14	Celltech Therapeutics Limited	Recombinant antibody
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
EP0768377A1 (en)	1988-09-02	1997-04-16	Protein Engineering Corporation	Generation and selection of recombinant varied binding proteins
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
AU634186B2 (en)	1988-11-11	1993-02-18	Medical Research Council	Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US6267964B1 (en)	1989-08-01	2001-07-31	Affibody Technology Sweden Ab	Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
SE509359C2 (en)	1989-08-01	1999-01-18	Cemu Bioteknik Ab	Use of stabilized protein or peptide conjugates for the preparation of a drug
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US5780225A (en)	1990-01-12	1998-07-14	Stratagene	Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en)	1990-01-11	1991-08-05	Molecular Affinities Corporation	Production of antibodies using gene libraries
ATE139258T1 (en)	1990-01-12	1996-06-15	Cell Genesys Inc	GENERATION OF XENOGENE ANTIBODIES
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
EP0542810A1 (en)	1990-08-02	1993-05-26	B.R. Centre Limited	Methods for the production of proteins with a desired function
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69127627T2 (en)	1990-08-29	1998-02-19	Genpharm Int	Production and Use Non-human transgene heterologous antibodies for production
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en)	1990-09-28	1997-12-16	Ixsys, Incorporated	Surface expression libraries of heteromeric receptors
DK0564531T3 (en)	1990-12-03	1998-09-28	Genentech Inc	Enrichment procedure for variant proteins with altered binding properties
ATE269401T1 (en)	1991-04-10	2004-07-15	Scripps Research Inst	LIBRARIES OF HETERODIMERIC RECEPTORS USING PHAGEMIDS
GB9112536D0 (en)	1991-06-11	1991-07-31	Celltech Ltd	Chemical compounds
GB9113120D0 (en)	1991-06-18	1991-08-07	Kodak Ltd	Photographic processing apparatus
PT1024191E (en)	1991-12-02	2008-12-22	Medical Res Council	Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
DE69334258D1 (en)	1992-08-21	2009-02-26	Univ Bruxelles	Immunoglobulins without a light chain
AU696293B2 (en)	1993-12-08	1998-09-03	Genzyme Corporation	Process for generating specific antibodies
WO1995020401A1 (en)	1994-01-31	1995-08-03	Trustees Of Boston University	Polyclonal antibody libraries
US5516637A (en)	1994-06-10	1996-05-14	Dade International Inc.	Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (en)	1996-01-24	1999-11-15	チッソ株式会社	Method for producing acryloxypropyl silane
ATE279947T1 (en)	1996-03-18	2004-11-15	Univ Texas	IMMUNOGLOBULIN-LIKE DOMAIN WITH INCREASED HALF-LIFE TIMES
DE19653722C2 (en)	1996-12-10	2000-06-29	Brose Fahrzeugteile	Adjustment device acting on both sides
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
IL131406A0 (en)	1997-02-21	2001-01-28	Genentech Inc	Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies
GB9720054D0 (en)	1997-09-19	1997-11-19	Celltech Therapeutics Ltd	Biological products
WO1999037791A1 (en)	1998-01-23	1999-07-29	Vlaams Interuniversitair Instituut Voor Biotechnologie	Multipurpose antibody derivatives
GB9812545D0 (en)	1998-06-10	1998-08-05	Celltech Therapeutics Ltd	Biological products
US7608681B2 (en)	1999-12-24	2009-10-27	Genentech, Inc.	Methods and compositions for prolonging elimination half-times of bioactive compounds
US7211395B2 (en)	2001-03-09	2007-05-01	Dyax Corp.	Serum albumin binding moieties
AU2003245664A1 (en)	2002-06-21	2004-01-06	Dyax Corporation	Serum protein-associated target-specific ligands and identification method therefor
JP2006512895A (en)	2002-06-28	2006-04-20	ドマンティスリミテッド	Ligand
US9321832B2 (en)	2002-06-28	2016-04-26	Domantis Limited	Ligand
WO2004051268A1 (en)	2002-12-03	2004-06-17	Celltech R & D Limited	Assay for identifying antibody producing cells
GB0312481D0 (en)	2003-05-30	2003-07-09	Celltech R&D Ltd	Antibodies
GB0315457D0 (en)	2003-07-01	2003-08-06	Celltech R&D Ltd	Biological products
GB0315450D0 (en)	2003-07-01	2003-08-06	Celltech R&D Ltd	Biological products
EP1644412B2 (en)	2003-07-01	2018-08-08	UCB Biopharma SPRL	Modified antibody fab fragments
GB0411186D0 (en)	2004-05-19	2004-06-23	Celltech R&D Ltd	Biological products
JP2008500830A (en)	2004-06-01	2008-01-17	ドマンティスリミテッド	Bispecific fusion antibodies with increased serum half-life
EP1877073B1 (en)	2004-12-01	2013-09-25	The Secretary of State for Health	Non-cytotoxic protein conjugates
GB0506912D0 (en)	2005-04-05	2005-05-11	Celltech R&D Ltd	Biological products
CA2700714C (en) *	2007-09-26	2018-09-11	Ucb Pharma S.A.	Dual specificity antibody fusions
DK2334705T3 (en)	2008-09-26	2017-03-27	Ucb Biopharma Sprl	BIOLOGICAL PRODUCTS
MA33122B1 (en) *	2009-02-17	2012-03-01	Ucb Pharma Sa	Antibody molecules with quality for human ox40
JP2012532620A (en)	2009-07-16	2012-12-20	グラクソグループリミテッド	Improved antiserum albumin binding single variable domain
ES2667258T3 (en)	2009-09-10	2018-05-10	Ucb Biopharma Sprl	Multivalent antibodies
GB201005063D0 (en) *	2010-03-25	2010-05-12	Ucb Pharma Sa	Biological products
GB0920127D0 (en) *	2009-11-17	2009-12-30	Ucb Pharma Sa	Antibodies
GB201000467D0 (en)	2010-01-12	2010-02-24	Ucb Pharma Sa	Antibodies

2012
- 2012-11-09 SG SG11201401649VA patent/SG11201401649VA/en unknown
- 2012-11-09 SI SI201231119T patent/SI2776466T1/en unknown
- 2012-11-09 WO PCT/EP2012/072335 patent/WO2013068571A1/en active Application Filing
- 2012-11-09 LT LTEP12801467.7T patent/LT2776466T/en unknown
- 2012-11-09 CN CN201280055064.0A patent/CN103946237B/en active Active
- 2012-11-09 PT PT128014677T patent/PT2776466T/en unknown
- 2012-11-09 JP JP2014540494A patent/JP6411214B2/en active Active
- 2012-11-09 EP EP12801467.7A patent/EP2776466B1/en active Active
- 2012-11-09 EA EA201400568A patent/EA033766B1/en not_active IP Right Cessation
- 2012-11-09 MX MX2014005546A patent/MX351502B/en active IP Right Grant
- 2012-11-09 AU AU2012335496A patent/AU2012335496B2/en active Active
- 2012-11-09 HU HUE12801467A patent/HUE037142T2/en unknown
- 2012-11-09 US US14/356,181 patent/US9803004B2/en active Active
- 2012-11-09 KR KR1020147015678A patent/KR102048382B1/en active IP Right Grant
- 2012-11-09 ES ES12801467.7T patent/ES2649098T3/en active Active
- 2012-11-09 BR BR112014011304-1A patent/BR112014011304B1/en active IP Right Grant
- 2012-11-09 CA CA2856216A patent/CA2856216C/en active Active
- 2012-11-09 IN IN3451DEN2014 patent/IN2014DN03451A/en unknown
- 2012-11-09 PL PL12801467T patent/PL2776466T3/en unknown
- 2012-11-09 DK DK12801467.7T patent/DK2776466T3/en active
2013
- 2013-04-12 NO NO13716781A patent/NO2839445T3/no unknown
2014
- 2014-04-24 IL IL23222614A patent/IL232226B/en active IP Right Grant
2017
- 2017-10-23 HR HRP20171608TT patent/HRP20171608T1/en unknown
- 2017-10-27 US US15/795,874 patent/US10023631B2/en active Active
- 2017-11-22 CY CY20171101222T patent/CY1119647T1/en unknown

Also Published As

Publication number	Publication date
IN2014DN03451A (en)	2015-06-05
US20140302033A1 (en)	2014-10-09
KR102048382B1 (en)	2019-11-25
HRP20171608T1 (en)	2017-12-01
BR112014011304A2 (en)	2017-05-16
CN103946237B (en)	2017-04-12
HUE037142T2 (en)	2018-08-28
CY1119647T1 (en)	2018-04-04
CA2856216A1 (en)	2013-05-16
IL232226B (en)	2019-11-28
NO2839445T3 (en)	2018-10-27
EP2776466B1 (en)	2017-08-23
KR20140093984A (en)	2014-07-29
EA201400568A1 (en)	2014-12-30
EP2776466A1 (en)	2014-09-17
MX2014005546A (en)	2014-06-04
SI2776466T1 (en)	2017-12-29
US9803004B2 (en)	2017-10-31
MX351502B (en)	2017-10-18
AU2012335496B2 (en)	2017-05-11
CN103946237A (en)	2014-07-23
JP6411214B2 (en)	2018-10-24
EA033766B1 (en)	2019-11-22
BR112014011304B1 (en)	2022-03-03
US10023631B2 (en)	2018-07-17
AU2012335496A1 (en)	2014-05-15
WO2013068571A1 (en)	2013-05-16
LT2776466T (en)	2017-11-27
IL232226A0 (en)	2014-06-30
US20180134774A1 (en)	2018-05-17
JP2014534978A (en)	2014-12-25
DK2776466T3 (en)	2017-11-20
PL2776466T3 (en)	2018-01-31
PT2776466T (en)	2017-11-30
ES2649098T3 (en)	2018-01-10
CA2856216C (en)	2021-01-12

Publication	Publication Date	Title
SG11201401649VA (en)	2014-07-30	Albumin binding antibodies and binding fragments thereof
HUS2100034I1 (en)	2021-10-28	Anti-angptl3 antibodies and uses thereof
IL282226A (en)	2021-05-31	St2 antigen binding proteins
EP2681239B8 (en)	2015-09-09	Antigen binding proteins
HK1200853A1 (en)	2015-08-14	Meditopes and meditope-binding antibodies and uses thereof
SG10201401681PA (en)	2014-07-30	Novel antigen binding proteins
EP2525813A4 (en)	2013-07-10	Anti-ilt5 antibodies and ilt5-binding antibody fragments
IL266452B (en)	2020-10-29	Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
HK1198832A1 (en)	2015-06-12	Fn14 binding proteins and uses thereof fn14
IL226157A0 (en)	2013-06-27	Antigen binding proteins